
IDYA Stock Forecast & Price Target
IDYA Analyst Ratings
Bulls say
IDEAYA Biosciences is experiencing a positive outlook due to promising developments in its targeted therapeutics, particularly with darovasertib, which has shown significant anti-tumor efficacy and improved visual acuity in patients with metastatic uveal melanoma. The company is advancing towards potential registration pathways with two Phase 3 trials currently underway, suggesting strong chances for successful outcomes and a substantial revenue upside, estimated to exceed $3.2 billion. Furthermore, the integration of darovasertib with crizotinib demonstrates enhanced efficacy and safety, bolstering investor confidence in the company's growth and market potential in precision oncology.
Bears say
The financial outlook for IDEAYA Biosciences Inc. is characterized by significant uncertainty stemming from the unpredictability of future revenues and expenses, compounded by its current non-revenue-generating status. Risk factors such as potential negative trial outcomes, regulatory hurdles, and challenges related to intellectual property could materially impede the commercialization of its therapeutic candidates, including darovasertib and IDE397. Additionally, the reliance on a limited pipeline and the potential for disappointing data in ongoing studies may undermine investor confidence and contribute to stock price volatility, suggesting substantial risk for the company’s financial performance.
This aggregate rating is based on analysts' research of Ideaya Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.
IDYA Analyst Forecast & Price Prediction
Start investing in IDYA
Order type
Buy in
Order amount
Est. shares
0 shares